4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Rating of “Moderate Buy” by Analysts

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been assigned a consensus rating of “Moderate Buy” from the ten brokerages that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $32.13.

FDMT has been the subject of several recent analyst reports. Bank of America decreased their price target on 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. BMO Capital Markets cut 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $40.00 to $15.00 in a research report on Monday, January 13th. Morgan Stanley dropped their price target on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a research report on Monday, January 13th. Leerink Partners decreased their price objective on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a report on Monday, January 13th. Finally, Royal Bank of Canada dropped their target price on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a report on Thursday, November 14th.

4D Molecular Therapeutics Trading Down 2.8 %

FDMT stock opened at $4.72 on Thursday. The firm has a market cap of $217.97 million, a PE ratio of -1.65 and a beta of 2.81. 4D Molecular Therapeutics has a 1 year low of $4.41 and a 1 year high of $36.25. The company has a fifty day simple moving average of $5.46 and a 200 day simple moving average of $9.10.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. nVerses Capital LLC acquired a new stake in 4D Molecular Therapeutics during the third quarter worth about $40,000. KLP Kapitalforvaltning AS acquired a new stake in shares of 4D Molecular Therapeutics during the 4th quarter worth approximately $48,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of 4D Molecular Therapeutics during the fourth quarter valued at approximately $50,000. PNC Financial Services Group Inc. raised its stake in shares of 4D Molecular Therapeutics by 66.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock valued at $51,000 after purchasing an additional 3,630 shares in the last quarter. Finally, Daiwa Securities Group Inc. raised its stake in shares of 4D Molecular Therapeutics by 5,291.8% in the fourth quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company’s stock valued at $55,000 after purchasing an additional 9,737 shares in the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.